Anbio BiotechnologyNNNN +2.88%24 Operating Margin % is 59.08% as of Dec. 2025, which is 36% above its 10-year median of 43.30. GuruFocus rates NNNN with a GF Score™ of 24/100. The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Anbio Biotechnology ranks better than 99.75% on this metric.
The historical rank and industry rank for Anbio Biotechnology's Operating Margin % or its related term are showing as below:
NNNN'
s Operating Margin % Range Over the Past 10 Years
Min: 24.37 Med: 43.3 Max: 66.71
Current: 66.69
NNNN's Operating Margin % is ranked better than 99.75% of 815
companies
in the Medical Devices & Instruments industry
Industry Median: 3.41
vs NNNN: 66.69
Anbio Biotechnology's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Anbio Biotechnology Operating Margin % Related Terms
Anbio Biotechnology Operating Margin % Historical Data
* Premium members only.
The historical data trend for Anbio Biotechnology's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NNNN vs ANGO, OSUR, UTMD: Operating Margin % Comparison
For the Medical Instruments & Supplies subindustry, Anbio Biotechnology's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anbio Biotechnology Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anbio Biotechnology's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Anbio Biotechnology's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Anbio Biotechnology's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anbio Biotechnology (NNNN) has a Operating Margin % of 59.08% as of Dec. 2025. Operating margin is the ratio of total operating income to net sales. View historical data on Anbio Biotechnology and its competitors. This is 36% above median its historical median of 43.30. Over the past decade, Anbio Biotechnology's Operating Margin % has ranged from 24.37 to 66.71. According to the industry distribution chart, Anbio Biotechnology ranks #2 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 0.2%.
Is Anbio Biotechnology's Operating Margin % too high?
Anbio Biotechnology's current Operating Margin % of 59.08% is 36% above median its 10-year median of 43.30. Over the past 10 years, this metric has ranged from a low of 24.37 to a high of 66.71. The Medical Devices & Instruments industry median Operating Margin % is 3.41. Anbio Biotechnology's value of 59.08% is 1632.6% above this industry median. Based on the distribution chart, Anbio Biotechnology ranks #2 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Anbio Biotechnology has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Anbio Biotechnology's Operating Margin % compare to ANGO and OSUR?
According to the Medical Devices & Instruments industry distribution chart, Anbio Biotechnology ranks #2 out of 815 companies for Operating Margin %. This places Anbio Biotechnology in the top 0% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.41. Anbio Biotechnology's value of 59.08% is 1632.6% above this benchmark. Historically, Anbio Biotechnology's own Operating Margin % has ranged from 24.37 to 66.71 over the past decade. While the company's 10-year median is 43.30 vs. the industry median of 3.41, Anbio Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.41, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anbio Biotechnology's current Operating Margin % of 59.08% is 1632.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Anbio Biotechnology and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anbio Biotechnology's current Operating Margin % is 59.08%, which is 36% above median its own 10-year median of 43.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anbio Biotechnology stock overvalued right now?
Anbio Biotechnology (NNNN) has a current Operating Margin % of 59.08%. The current Operating Margin % is 59.08%, which is 36% above median its 10-year median of 43.30 and 1632.6% above the Medical Devices & Instruments industry median of 3.41. Anbio Biotechnology's overall GF Score™ is 24/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Anbio Biotechnology (NNNN), the current Operating Margin % is 59.08% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
24GF Score
Get the complete analysis for NNNN
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NNNN has been successfully added to your 
